METOCLOPRAMIDE-INDUCED PARKINSONISM DUE TO BILATERAL BASAL GANGLIA AND BRAIN STEM INVOLVEMENT IN A PATIENT WITH LARYNGEAL CARCINOMA

Larinks kanserli hastada beyin sapı ve bazal ganglion tutulumu ile birlikte metoklopramidin indüklediği parkinsonizm

Ali İnal¹, Ertuğrul Uzar², Muhammed Ali Kaplan¹, Mehmet Küküçüner³, Zuhat Urakcı¹, Faysal Ekici³, Abdurrahman İşlıkdoğan¹

ABSTRACT

Parkinsonism and basal ganglion involvement due to antiemetic drugs, such as metoclopramide, is rarely encountered. However, bilateral basal ganglia and brain stem involvement has not yet been reported in patients with drug-induced Parkinsonism.

A 52-year-old male patient with laryngeal carcinoma was treated with docetaxel, cisplatin, and 5-fluorouracil (DCF) chemotherapy. Because of severe nausea and vomiting 15 days after the first course of chemotherapy, metoclopramide was administered. Parkinsonism symptoms were observed on the 6th day of metoclopramide therapy. Cerebral MRI revealed bilateral basal ganglia and brain stem involvement. Metoclopramide therapy was promptly discontinued and oral biperiden was commenced. Parkinsonism findings almost completely improved on his control examination performed after one month. He was not given metoclopramide during further chemotherapy courses. Cerebral MRI taken after three months revealed that the lesions have completely relieved.

This is an extremely rare case of metoclopramide-induced Parkinsonism together with brain stem and basal ganglion involvement in a patient with laryngeal carcinoma treated by chemotherapy. The clinical and radiological improvement was observed with the cessation of the causative drug and biperiden therapy. J Clin Exp Invest 2012; 3(4): 536-538

Key words: Parkinsonism, metoclopramide, laryngeal carcinoma

INTRODUCTION

The drug-induced Parkinsonism accounts for approximately 2.7% of these patients. Metoclopramide is a dopamine receptor antagonist and may occasionally cause extrapyramidal side effects due to its dopaminergic antagonistic effect. Parkinsonism and basal ganglion involvement due to antiemetic drugs, such as metoclopramide, is rarely reported, whereas bilateral basal ganglia and brain stem involvement has not yet been reported until now on the brain MRI of the patients with drug-in-

ÖZET

Metoklopramid gibi antiemetik ilaçlara bağlı parkinsonizm ve bazal ganglion tutulumu nadirdir. Ancak, bilateral bazal ganglion ve beyin sapı tutulumu ilaca bağlı parkinsonizm hastalarında henüz bildirilmemiştir.

duced Parkinsonism. We present the first case of metoclopramide-induced Parkinsonism together with brain stem and basal ganglion involvement in a patient with laryngeal carcinoma treated with chemotherapy.

CASE REPORT

A 52-year-old male patient with locally advanced laryngeal carcinoma. He started to receive a chemotherapy regimen consisted of docetaxel, cisplatin, and 5-fluorouracil (DCF). He was admitted to our clinic because of severe nausea and vomiting 15 days after the first course of chemotherapy. Fluid replacement and metoclopramide (oral, 20 mg daily) were commenced to control dehydration and vomiting. Tremor in the hands, dysarthria, mask face, restlessness, irritability and limited movement developed in the patient on the 6th day of metoclopramide therapy. Neurologic examination revealed akathisia, sialorrhea, hypomimia, bradykinesia, parkinsonian gait and tremor in all extremities. Drug-induced parkinsonism and akathisia (extrapyramidal side effect) were diagnosed for the patient by the consultation with the neurology department. Complete blood count, electrolytes, anti DNA, Vitamin B12, folic acid and thyroid functions were within the normal ranges. On his cerebral MRI, T1 hypointense and T2 hyperintense signal changes were determined in the bilateral basal ganglia, including putamen, globus pallidus and the head of the caudate nucleus, as well as in the mesencephalon area, including nucleus ruber and nucleus ruber (fig.1a,1b). Laryngeal cancer metastasis was not considered, because the contrast substance was not uptaken by the lesions on the contrast-enhanced MRI of the cerebrum.

Metoclopramide therapy was immediately discontinued and oral biperiden was started with the dose of 2 mg three times daily. Parkinsonism symptoms slightly improved on the 3rd day of biperiden therapy. Neurologic examination performed 15 days later revealed bilateral tremor in the hands of the patient has disappeared and limited movement and dysarthria have considerably regressed. The parkinsonian findings almost completely improved on control examination after one month. The lesions in the basal ganglion were absent on the follow-up MRI of the cerebrum. However, T1 hypointense and T2 hyperintense changes were observed on the brain stem lesions, including nucleus ruber (Fig.1c,1d). Biperiden therapy was gradually decreased and discontinued. DCF course was repeated for three times. Metoclopramide was not preferred as an antiemetic in this patient. Parkinsonism complaints did not recur, and the patient has been free of any associated symptoms.

DISCUSSION

Symptoms due to the damage of the extrapyramidal system, such as parkinsonism, acute dystonic reaction, akathisia, motor tics, myoclonus and tardive dyskinesia, may be seen. One of these symptoms may occur alone, or they may present together. It has been put forward that the pathogenesis of drug-induced Parkinsonism results from the imbalance between acetylcholine and dopamine in the central nervous system (CNS). Extrapyramidal side effects commonly appear 24 hours after metoclopramide is started and generally disappears 24 hours after discontinuation. Extrapyramidal side effects quite rarely persist for weeks or months. In this case, dysarthria, irritability, desire to move continuously, slowing down in walking, and tremor were developed after 24 hours following metoclopramide given in order to prevent nausea. Metoclopramide-induced Parkinsonism and akathisia, rather than idiopathic
Parkinson’s disease, was considered owing to the fact that he had no history of Parkinson’s disease and that his complaints had begun bilaterally and acute. No other reason was found that could lead to parkinsonism and akathisia. It has been reported that certain chemotherapeutic agents cause parkinsonism. Parkinsonism symptoms were not present in this case during the first course of anticancer therapy. Following the second course of anticancer therapy, parkinsonism was seen at the same time with metoclopramide. After the relief of parkinsonism, it did not recur following the third course of anticancer therapy. Moreover, metoclopramide-induced parkinsonism has been reported more commonly than anticancer drug-induced parkinsonism. Consequently, Parkinsonism and akathisia were not attributed to the anticancer therapy. Moreover, they gradually disappeared with the cessation of metoclopramide. Metoclopramide-induced Parkinsonism and akathisia together with the involvement of basal ganglion, thalamus and brain stem in cancer patients has not yet been reported. However, in Parkinsonism caused by toxic substances, such as carbon monoxide and manganese, globus pallidus, substantia nigra, nucleus ruber and brain stem can also be involved. Parkinsonism may be developed due to the involvement of the extrapyramidal system, including brain stem, substantia nigra, striatum and thalamus.

The cerebral MRI performed in the subacute period revealed bilateral involvement of the putamen, as well as globus pallidus, the head of the caudate nucleus, substantia nigra from the mesencephalon to pons, and nucleus rubber in this case. This shows that the effect of metoclopramide on the extrapyramidal pathways is similar with that of manganese and carbon monoxide intoxication. Parkinsonism complaints of the patient decreased within one month with chemotherapy. Caudate nucleus, globus pallidus and putamen lesions of the present case disappeared on his control MRI performed after three months. Although the Parkinsonism signs have disappeared, nucleus rubber lesions persisted at the mesencephalon level.

Metoclopramide-induced Parkinsonism and akathisia can be seen rarely. Putamen, globus pallidus, the head of caudate nucleus and nucleus rubber may also be affected in such patients. In a case of metoclopramide-induced Parkinsonism, cerebral MRI should be performed to visualize the major damage in the extrapyramidal system.

REFERENCES